Danaher Corporation (DHR)
| Market Cap | 124.65B -11.2% |
| Revenue (ttm) | 24.78B +4.0% |
| Net Income | 3.69B -2.0% |
| EPS | 5.18 +0.4% |
| Shares Out | 707.77M |
| PE Ratio | 34.14 |
| Forward PE | 20.61 |
| Dividend | $1.60 (0.91%) |
| Ex-Dividend Date | Jun 26, 2026 |
| Volume | 2,914,087 |
| Open | 177.74 |
| Previous Close | 179.87 |
| Day's Range | 175.50 - 179.34 |
| 52-Week Range | 160.93 - 242.80 |
| Beta | 0.83 |
| Analysts | Strong Buy |
| Price Target | 246.09 (+39.74%) |
| Earnings Date | Jul 21, 2026 |
About DHR
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufact... [Read more]
Financial Performance
In 2025, Danaher's revenue was $24.57 billion, an increase of 2.90% compared to the previous year's $23.88 billion. Earnings were $3.61 billion, a decrease of -7.31%.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for DHR stock is "Strong Buy." The 12-month stock price target is $246.09, which is an increase of 39.74% from the latest price.
News
Danaher price target lowered to $230 from $270 at HSBC
HSBC lowered the firm’s price target on Danaher (DHR) to $230 from $270 and keeps a Buy rating on the shares. The firm says market expectations on life science tools…
Danaher initiated with a Buy at DZ Bank
DZ Bank initiated coverage of Danaher (DHR) with a Buy rating and $210 price target
Danaher assumed with Peer Perform at Wolfe Research
As previously reported, Wolfe Research analyst Mike Polark downgraded Danaher (DHR) to Peer Perform from Outperform with no price target after assuming coverage of the name. Growth forward and backwar...
Danaher assumed with Peer Perform from Outperform at Wolfe Research
Wolfe Research analyst Mike Polark downgraded Danaher (DHR) to Peer Perform from Outperform after assuming coverage of the name.
SCIEX Advances the ZenoTOF Line With Platform-Wide Expansions in Software, Integrations, and Key Collaborations
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #massspec--SCIEX advances the ZenoTOF line with platform-wide expansions in software, integrations, and key collaborations.
SCIEX Launches the novus V55 System With SCIEX OS 5.0 Software and AI Enablement Tools
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #V55--SCIEX launches the novus V55 system with SCIEX OS 5.0 software and AI enablement tools.
Integrated DNA Technologies enters collaboration with Illumina
Integrated DNA Technologies (DHR) announced a strategic collaboration with Illumina (ILMN) to enable a DRAGEN secondary analysis pipeline for IDT xGen FFPE and cfDNA next generation sequencing library...
Danaher resumed with a Buy at Citi
Citi resumed coverage of Danaher (DHR) with a Buy rating and $230 price target following a suspension of the rating. Danaher reiterated its fiscal 2026 core growth guidance when reporting…
Danaher resumed with an Outperform at RBC Capital
RBC Capital resumed coverage of Danaher (DHR) with an Outperform rating and $200 price target The firm sees the company’s growth recovering with the bioprocess market improving. A sustained bioprocess...
Danaher Transcript: Bank of America Global Healthcare Conference 2026
Solid first quarter with 300 basis points of core growth, strong bioprocessing and diagnostics momentum, and robust performance in life sciences. Guidance for 3%-6% organic growth is maintained, with headwinds expected to fade and capital deployment focused on M&A and strategic investments.
Danaher to Present at Bank of America Securities Healthcare Conference
WASHINGTON, May 6, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Heal...
Danaher Announces Quarterly Dividend
WASHINGTON, May 5, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stoc...
Danaher Transcript: AGM 2026
The meeting covered director elections, auditor reappointment, executive compensation, and incentive plan approval, all passing with strong majorities. Financial results showed $24.6B in revenue, high margins, and strong recurring revenue, with a focus on life sciences and diagnostics.
Masimo shareholders approve acquisition by Danaher
Masimo (MASI) announced that its stockholders voted in favor of the proposal to adopt the previously announced Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo,…
Masimo Shareholders Approve Acquisition by Danaher
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to...
Agilent appoints Michael Buckner as CLO
Agilent Technologies (A) announced the appointment of Michael Buckner as chief legal officer. Buckner joins Agilent from Danaher Corp. (DHR), where he served as vice president, deputy general counsel,...
Danaher reaches $172.5 million settlement with shareholders over post-pandemic outlook
Danaher reached a $172.5 million settlement with shareholders who accused the diagnostics and life-sciences company of defrauding them by overstating demand for its equipment as the worst of the COV...
Danaher Announces Pricing of Euro-Denominated Senior Notes Offering
WASHINGTON, April 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today that it has priced an offering of the following euro-denominated senior notes (the "Offering"): €...
Danaher price target lowered to $250 from $270 at UBS
UBS lowered the firm’s price target on Danaher (DHR) to $250 from $270 and keeps a Buy rating on the shares. The firm still sees potential upside despite respiratory headwinds,…
Danaher price target lowered to $245 from $249 at Baird
Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Danaher (DHR) to $245 from $249 and keeps an Outperform rating on the shares. The firm updated its model…
Danaher price target lowered to $235 from $275 at Guggenheim
Guggenheim analyst Subbu Nambi lowered the firm’s price target on Danaher (DHR) to $235 from $275 and keeps a Buy rating on the shares. Q1 results were about as the…
Danaher price target raised to $245 from $240 at Jefferies
Jefferies analyst Tycho Peterson raised the firm’s price target on Danaher (DHR) to $245 from $240 and keeps a Buy rating on the shares after a “solid” Q1 report. Headwinds…
Danaher Earnings Call Transcript: Q1 2026
Q1 2026 saw strong execution, with core revenue up 0.5% and adjusted EPS up 9.5% year-over-year. Bioprocessing and life sciences offset respiratory headwinds, and the Masimo acquisition is expected to be accretive. Full-year guidance was raised for adjusted EPS.
Danaher Earnings release: Q1 2026
Danaher released its Q1 2026 earnings on April 21, 2026, summarizing the period's financial results.